Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2024Open Access

Neutralization and Binding Capability of SARS-CoV-2 Variants by/of IgG Antibodies of Early COVID-19 Convalescent Inactivated Sera based on Indirect ELISA

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBehzad HussainShanxi UniversityPZPeizhe ZhaoChinese Academy of Medical Sciences & Peking Union Medical CollegeBYBo YangTongji University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hussain et al. (2024) studied this question.

synapsesocial.com/papers/68e69222b6db643587618b7ahttps://doi.org/10.20944/preprints202405.1313.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus‐22026
  2. 2Investigation of SARS-CoV-2 IgG Binding Capability to Variants of the SARS-CoV-2 Virus2024
  3. 3In Silico Evaluation of Ten Monoclonal Antibodies Neutralization Power of SARS-CoV-2 Variants EG.5, BA.2.86 and JN.12024
  4. 4Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge2023 · 18 citations
  5. 5Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines2021 · 12 citations